A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors

Trial Profile

A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs MGA 012 (Primary) ; MGD 009 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MacroGenics
  • Most Recent Events

    • 25 Jan 2018 New trial record
    • 24 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
    • 24 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top